Mark Vincent
Direktor/Vorstandsmitglied bei APTOSE BIOSCIENCES INC.
Vermögen: 502 $ am 30.04.2024
Aktive Positionen von Mark Vincent
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| APTOSE BIOSCIENCES INC. | Direktor/Vorstandsmitglied | 19.09.2007 | - |
| Independent Dir/Board Member | 19.09.2007 | - | |
| Sarissa, Inc. | Direktor/Vorstandsmitglied | 18.01.2011 | - |
| Vorstandsvorsitzender | 01.01.2000 | - | |
| Gründer | 01.01.2000 | - | |
| University of Western Ontario | Corporate Officer/Principal | 01.01.2008 | - |
Karriereverlauf von Mark Vincent
Ehemalige bekannte Positionen von Mark Vincent
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
DRI Capital, Inc.
 DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Direktor/Vorstandsmitglied | - | - |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 01.01.2000 | - |
Ausbildung von Mark Vincent
| University of Cape Town | Doctorate Degree |
Statistik
International
| Kanada | 6 |
| Südafrika | 2 |
Operativ
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
| Sarissa, Inc. | |
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Finance |
- Börse
- Insiders
- Mark Vincent
- Erfahrung
